Cytoreductive  ||| S:0 E:14 ||| NNP
Surgery  ||| S:14 E:22 ||| NNP
and  ||| S:22 E:26 ||| CC
Hyperthermic  ||| S:26 E:39 ||| NNP
Intraperitoneal  ||| S:39 E:55 ||| NNP
Chemotherapy  ||| S:55 E:68 ||| NNP
for  ||| S:68 E:72 ||| IN
Peritoneal  ||| S:72 E:83 ||| NNP
Dissemination  ||| S:83 E:97 ||| NNP
from  ||| S:97 E:102 ||| IN
Small  ||| S:102 E:108 ||| NNP
Bowel  ||| S:108 E:114 ||| NNP
Malignancy ||| S:114 E:124 ||| NNP
:  ||| S:124 E:126 ||| :
Results  ||| S:126 E:134 ||| NNS
from  ||| S:134 E:139 ||| IN
a  ||| S:139 E:141 ||| DT
Single  ||| S:141 E:148 ||| NNP
Specialized  ||| S:148 E:160 ||| NNP
Center  ||| S:160 E:167 ||| NNP
Peritoneal  ||| S:167 E:178 ||| NNP
dissemination  ||| S:178 E:192 ||| NN
is  ||| S:192 E:195 ||| VBZ
a  ||| S:195 E:197 ||| DT
frequent  ||| S:197 E:206 ||| JJ
pattern  ||| S:206 E:214 ||| NN
of  ||| S:214 E:217 ||| IN
recurrence  ||| S:217 E:228 ||| NN
and  ||| S:228 E:232 ||| CC
metastasis  ||| S:232 E:243 ||| NN
of  ||| S:243 E:246 ||| IN
small  ||| S:246 E:252 ||| JJ
bowel  ||| S:252 E:258 ||| JJ
malignancy  ||| S:258 E:269 ||| NN
( ||| S:269 E:270 ||| -LRB-
SBM ||| S:270 E:273 ||| NNP
) ||| S:273 E:274 ||| -RRB-
.  ||| S:274 E:276 ||| .
However ||| S:276 E:283 ||| RB
,  ||| S:283 E:285 ||| ,
the  ||| S:285 E:289 ||| DT
survival  ||| S:289 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
patients  ||| S:301 E:310 ||| NNS
with  ||| S:310 E:315 ||| IN
peritoneal  ||| S:315 E:326 ||| JJ
dissemination  ||| S:326 E:340 ||| NN
from  ||| S:340 E:345 ||| IN
SBM  ||| S:345 E:349 ||| NNP
is  ||| S:349 E:352 ||| VBZ
not  ||| S:352 E:356 ||| RB
clear ||| S:356 E:361 ||| JJ
,  ||| S:361 E:363 ||| ,
and  ||| S:363 E:367 ||| CC
there  ||| S:367 E:373 ||| EX
is  ||| S:373 E:376 ||| VBZ
no  ||| S:376 E:379 ||| DT
consensus  ||| S:379 E:389 ||| NN
on  ||| S:389 E:392 ||| IN
the  ||| S:392 E:396 ||| DT
treatment  ||| S:396 E:406 ||| NN
for  ||| S:406 E:410 ||| IN
it ||| S:410 E:412 ||| PRP
.  ||| S:412 E:414 ||| .
A  ||| S:414 E:416 ||| DT
total  ||| S:416 E:422 ||| NN
of  ||| S:422 E:425 ||| IN
31  ||| S:425 E:428 ||| CD
selected  ||| S:428 E:437 ||| JJ
patients  ||| S:437 E:446 ||| NNS
with  ||| S:446 E:451 ||| IN
peritoneal  ||| S:451 E:462 ||| JJ
dissemination  ||| S:462 E:476 ||| NN
from  ||| S:476 E:481 ||| IN
SBM  ||| S:481 E:485 ||| NNP
were  ||| S:485 E:490 ||| VBD
treated  ||| S:490 E:498 ||| VBN
by  ||| S:498 E:501 ||| IN
cytoreductive  ||| S:501 E:515 ||| JJ
surgery  ||| S:515 E:523 ||| NN
( ||| S:523 E:524 ||| -LRB-
CRS ||| S:524 E:527 ||| NNP
)  ||| S:527 E:529 ||| -RRB-
and  ||| S:529 E:533 ||| CC
hyperthermic  ||| S:533 E:546 ||| FW
intraperitoneal  ||| S:546 E:562 ||| FW
chemotherapy  ||| S:562 E:575 ||| FW
( ||| S:575 E:576 ||| -LRB-
HIPEC ||| S:576 E:581 ||| NNP
)  ||| S:581 E:583 ||| -RRB-
between  ||| S:583 E:591 ||| IN
January  ||| S:591 E:599 ||| NNP
2006  ||| S:599 E:604 ||| CD
and  ||| S:604 E:608 ||| CC
January  ||| S:608 E:616 ||| NNP
2014 ||| S:616 E:620 ||| CD
.  ||| S:620 E:622 ||| .
The  ||| S:622 E:626 ||| DT
major  ||| S:626 E:632 ||| JJ
focus  ||| S:632 E:638 ||| NN
of  ||| S:638 E:641 ||| IN
this  ||| S:641 E:646 ||| DT
study  ||| S:646 E:652 ||| NN
was  ||| S:652 E:656 ||| VBD
overall  ||| S:656 E:664 ||| JJ
survival ||| S:664 E:672 ||| NN
,  ||| S:672 E:674 ||| ,
as  ||| S:674 E:677 ||| RB
well  ||| S:677 E:682 ||| RB
as  ||| S:682 E:685 ||| IN
morbidity  ||| S:685 E:695 ||| NN
and  ||| S:695 E:699 ||| CC
mortality ||| S:699 E:708 ||| NN
.  ||| S:708 E:710 ||| .
Twenty-five  ||| S:710 E:722 ||| CD
patients  ||| S:722 E:731 ||| NNS
had  ||| S:731 E:735 ||| VBD
small  ||| S:735 E:741 ||| JJ
bowel  ||| S:741 E:747 ||| NN
adenocarcinoma  ||| S:747 E:762 ||| NNS
( ||| S:762 E:763 ||| -LRB-
SBA ||| S:763 E:766 ||| NNP
) ||| S:766 E:767 ||| -RRB-
,  ||| S:767 E:769 ||| ,
and  ||| S:769 E:773 ||| CC
six  ||| S:773 E:777 ||| CD
patients  ||| S:777 E:786 ||| NNS
had  ||| S:786 E:790 ||| VBD
non-adenocarcinoma  ||| S:790 E:809 ||| NNP
SBM ||| S:809 E:812 ||| NNP
.  ||| S:812 E:814 ||| .
HIPEC  ||| S:814 E:820 ||| NNP
was  ||| S:820 E:824 ||| VBD
performed  ||| S:824 E:834 ||| VBN
on  ||| S:834 E:837 ||| IN
21  ||| S:837 E:840 ||| CD
patients ||| S:840 E:848 ||| NNS
,  ||| S:848 E:850 ||| ,
and  ||| S:850 E:854 ||| CC
21  ||| S:854 E:857 ||| CD
patients  ||| S:857 E:866 ||| NNS
received  ||| S:866 E:875 ||| VBD
complete  ||| S:875 E:884 ||| JJ
cytoreduction ||| S:884 E:897 ||| NN
.  ||| S:897 E:899 ||| .
There  ||| S:899 E:905 ||| EX
was  ||| S:905 E:909 ||| VBD
no  ||| S:909 E:912 ||| DT
treatment-related  ||| S:912 E:930 ||| JJ
mortality ||| S:930 E:939 ||| NN
,  ||| S:939 E:941 ||| ,
and  ||| S:941 E:945 ||| CC
eight  ||| S:945 E:951 ||| CD
( ||| S:951 E:952 ||| -LRB-
25.8  ||| S:952 E:957 ||| NNP
% ||| S:957 E:958 ||| NN
)  ||| S:958 E:960 ||| -RRB-
patients  ||| S:960 E:969 ||| NNS
had  ||| S:969 E:973 ||| VBD
grade  ||| S:973 E:979 ||| CD
3-4  ||| S:979 E:983 ||| CD
complications ||| S:983 E:996 ||| NNS
.  ||| S:996 E:998 ||| .
Until  ||| S:998 E:1004 ||| IN
the  ||| S:1004 E:1008 ||| DT
latest  ||| S:1008 E:1015 ||| JJS
follow-up ||| S:1015 E:1024 ||| JJ
,  ||| S:1024 E:1026 ||| ,
the  ||| S:1026 E:1030 ||| DT
median  ||| S:1030 E:1037 ||| JJ
survival  ||| S:1037 E:1046 ||| NN
of  ||| S:1046 E:1049 ||| IN
31  ||| S:1049 E:1052 ||| CD
patients  ||| S:1052 E:1061 ||| NNS
after  ||| S:1061 E:1067 ||| IN
CRS  ||| S:1067 E:1071 ||| NNP
and  ||| S:1071 E:1075 ||| CC
HIPEC  ||| S:1075 E:1081 ||| NNP
was  ||| S:1081 E:1085 ||| VBD
36 months  ||| S:1085 E:1095 ||| CD
( ||| S:1095 E:1096 ||| -LRB-
range  ||| S:1096 E:1102 ||| NN
5-95 months ||| S:1102 E:1113 ||| CD
) ||| S:1113 E:1114 ||| -RRB-
,  ||| S:1114 E:1116 ||| ,
and  ||| S:1116 E:1120 ||| CC
the  ||| S:1120 E:1124 ||| DT
median  ||| S:1124 E:1131 ||| JJ
survival  ||| S:1131 E:1140 ||| NN
after  ||| S:1140 E:1146 ||| IN
diagnosis  ||| S:1146 E:1156 ||| NN
was  ||| S:1156 E:1160 ||| VBD
51 months  ||| S:1160 E:1170 ||| CD
( ||| S:1170 E:1171 ||| -LRB-
range  ||| S:1171 E:1177 ||| NN
18-101 months ||| S:1177 E:1190 ||| CD
) ||| S:1190 E:1191 ||| -RRB-
.  ||| S:1191 E:1193 ||| .
For  ||| S:1193 E:1197 ||| IN
25  ||| S:1197 E:1200 ||| CD
patients  ||| S:1200 E:1209 ||| NNS
with  ||| S:1209 E:1214 ||| IN
peritoneal  ||| S:1214 E:1225 ||| JJ
carcinomatosis  ||| S:1225 E:1240 ||| NN
from  ||| S:1240 E:1245 ||| IN
SBA ||| S:1245 E:1248 ||| NNP
,  ||| S:1248 E:1250 ||| ,
the  ||| S:1250 E:1254 ||| DT
median  ||| S:1254 E:1261 ||| JJ
survival  ||| S:1261 E:1270 ||| NN
after  ||| S:1270 E:1276 ||| IN
CRS  ||| S:1276 E:1280 ||| NNP
and  ||| S:1280 E:1284 ||| CC
HIPEC  ||| S:1284 E:1290 ||| NNP
was  ||| S:1290 E:1294 ||| VBD
36 months  ||| S:1294 E:1304 ||| CD
( ||| S:1304 E:1305 ||| -LRB-
range  ||| S:1305 E:1311 ||| NN
6-95 months ||| S:1311 E:1322 ||| CD
) ||| S:1322 E:1323 ||| -RRB-
,  ||| S:1323 E:1325 ||| ,
and  ||| S:1325 E:1329 ||| CC
the  ||| S:1329 E:1333 ||| DT
median  ||| S:1333 E:1340 ||| JJ
survival  ||| S:1340 E:1349 ||| NN
after  ||| S:1349 E:1355 ||| IN
diagnosis  ||| S:1355 E:1365 ||| NN
was  ||| S:1365 E:1369 ||| VBD
50 months  ||| S:1369 E:1379 ||| CD
( ||| S:1379 E:1380 ||| -LRB-
range  ||| S:1380 E:1386 ||| NN
18-101 months ||| S:1386 E:1399 ||| CD
) ||| S:1399 E:1400 ||| -RRB-
.  ||| S:1400 E:1402 ||| .
Multivariate  ||| S:1402 E:1415 ||| JJ
analysis  ||| S:1415 E:1424 ||| NN
revealed  ||| S:1424 E:1433 ||| VBD
that  ||| S:1433 E:1438 ||| DT
peritoneal  ||| S:1438 E:1449 ||| JJ
cancer  ||| S:1449 E:1456 ||| NN
index  ||| S:1456 E:1462 ||| NN
< ||| S:1462 E:1463 ||| SYM
15  ||| S:1463 E:1466 ||| CD
( ||| S:1466 E:1467 ||| -LRB-
p = 0.009 ||| S:1467 E:1476 ||| NNP
)  ||| S:1476 E:1478 ||| -RRB-
and  ||| S:1478 E:1482 ||| CC
HIPEC  ||| S:1482 E:1488 ||| NNP
( ||| S:1488 E:1489 ||| -LRB-
p   ||| S:1489 E:1491 ||| NNP
< ||| S:1491 E:1492 ||| SYM
 0.001 ||| S:1492 E:1498 ||| NNP
)  ||| S:1498 E:1500 ||| -RRB-
were  ||| S:1500 E:1505 ||| VBD
independent  ||| S:1505 E:1517 ||| JJ
predictors  ||| S:1517 E:1528 ||| NN
of  ||| S:1528 E:1531 ||| IN
better  ||| S:1531 E:1538 ||| JJR
survival  ||| S:1538 E:1547 ||| NN
in  ||| S:1547 E:1550 ||| IN
patients  ||| S:1550 E:1559 ||| NNS
with  ||| S:1559 E:1564 ||| IN
peritoneal  ||| S:1564 E:1575 ||| JJ
dissemination  ||| S:1575 E:1589 ||| NN
from  ||| S:1589 E:1594 ||| IN
SBM  ||| S:1594 E:1598 ||| NNP
treated  ||| S:1598 E:1606 ||| VBD
by  ||| S:1606 E:1609 ||| IN
CRS  ||| S:1609 E:1613 ||| NNP
and  ||| S:1613 E:1617 ||| CC
HIPEC ||| S:1617 E:1622 ||| NNP
.  ||| S:1622 E:1624 ||| .
Until  ||| S:1624 E:1630 ||| IN
more  ||| S:1630 E:1635 ||| JJR
data  ||| S:1635 E:1640 ||| NNS
become  ||| S:1640 E:1647 ||| VBP
available ||| S:1647 E:1656 ||| JJ
,  ||| S:1656 E:1658 ||| ,
a  ||| S:1658 E:1660 ||| DT
reasonable  ||| S:1660 E:1671 ||| JJ
strategy  ||| S:1671 E:1680 ||| NN
for  ||| S:1680 E:1684 ||| IN
the  ||| S:1684 E:1688 ||| DT
treatment  ||| S:1688 E:1698 ||| NN
of  ||| S:1698 E:1701 ||| IN
SBM  ||| S:1701 E:1705 ||| NNP
is  ||| S:1705 E:1708 ||| VBZ
CRS  ||| S:1708 E:1712 ||| NNP
and  ||| S:1712 E:1716 ||| CC
HIPEC ||| S:1716 E:1721 ||| NNP
.  ||| S:1721 E:1723 ||| .
It  ||| S:1723 E:1726 ||| PRP
can  ||| S:1726 E:1730 ||| MD
be  ||| S:1730 E:1733 ||| VB
applied  ||| S:1733 E:1741 ||| VBN
with  ||| S:1741 E:1746 ||| IN
acceptable  ||| S:1746 E:1757 ||| JJ
safety  ||| S:1757 E:1764 ||| NN
in  ||| S:1764 E:1767 ||| IN
selected  ||| S:1767 E:1776 ||| JJ
patients  ||| S:1776 E:1785 ||| NNS
with  ||| S:1785 E:1790 ||| IN
peritoneal  ||| S:1790 E:1801 ||| JJ
dissemination  ||| S:1801 E:1815 ||| NN
from  ||| S:1815 E:1820 ||| IN
SBM ||| S:1820 E:1823 ||| NNP
.  ||| S:1823 E:1825 ||| .
